Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic triple-negative breast cancer, drawn from the whole corpus: 164 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Cross-resistance between antibody-drug conjugates sharing a topoisomerase I payload.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
No biomarker selects patients for TROP2 drugs.
Brain metastases remain undertreated and are excluded from most trials.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Access: the new first-line drugs cost many times more than chemotherapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 27 changes by month →When this page itself was last checked or edited.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.
A milestone in how this cancer is treated.
PFS HR 0.
PFS HR 0.